2012/09/09 17:50

Ref EGFR mutation

EGFR mutation status is associated with response to anti-tyrosine kinase inhibitor (TKI).1 The drug erlotinib has been used with increasing success to treat patients with advanced lung cancer who carry mutated EGFR genes. Mutations in the EGFR gene can be a result of point mutations in exon 21, of which L858R is the most common, as well as deletions in exon 19 (15 base-pair deletion is the most commonly seen deletion).

Although mutations in the EGFR gene can be seen in any histological subtype of adenocarcinoma, epidemiologic studies have demonstrated that there is a strong association of EGFR mutation with female sex, Asian origin, and never smoker status.2 Therefore, this patient would most likely carry the EGFR mutation and benefit from treatment with TKI inhibitors.

References

  1. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004;101:13306-13311.
  2. Sun Y, Ren Y, Fang Z, et al. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. J Clin Oncol. 2010;28:4616-4620.

덧글

댓글 입력 영역